Turning the tide against cancer through sustained medical innovation: The pathway to progress

Amy Abernethy, Edward Abrahams, Anna Barker, Kenneth Buetow, Randy Burkholder, William S. Dalton, Margaret Foti, Felix Frueh, Richard B. Gaynor, Marcia Kean, Zeba Khan, Tracy Lessor, J. Leonard Lichtenfeld, John Mendelsohn, Laura Van'T Veer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

An ever-expanding understanding of the molecular basis of the more than 200 unique diseases collectively called cancer, combined with efforts to apply these insights to clinical care, is forming the foundation of an era of personalized medicine that promises to improve cancer treatment. At the same time, these extraordinary opportunities are occurring in an environment of intense pressure to contain rising healthcare costs. This environment presents a challenge to oncology research and clinical care, because both are becoming progressively more complex and expensive, and because the current tools to measure the cost and value of advances in care (e.g., comparative effectiveness research, cost-effectiveness analysis, and health technology assessments) are not optimized for an ecosystem moving toward personalized, patient-centered care. Reconciling this tension will be essential to maintaining progress in a cost-constrained environment, especially because emerging innovations in science (e.g., increasing identification of molecular biomarkers) and in clinical process (implementation of a learning healthcare system) hold potential to dramatically improve patient care, and may ultimately help address the burden of rising costs. For example, the rapid pace of innovation taking place within oncology calls for increased capability to integrate clinical research and care to enable continuous learning, so that lessons learned from each patient treated can inform clinical decision making for the next patient. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration. This article reflects and seeks to amplify the ongoing robust discussion and diverse perspectives brought to this issue by multiple stakeholders within the cancer community, and to consider how to frame the research and regulatory policies necessary to sustain progress against cancer in an environment of constrained resources.

Original languageEnglish (US)
Pages (from-to)1081-1086
Number of pages6
JournalClinical Cancer Research
Volume20
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Neoplasms
Research
Costs and Cost Analysis
Comparative Effectiveness Research
Learning
Biomedical Technology Assessment
Patient-Centered Care
Precision Medicine
Medical Oncology
Cost Control
Health Care Costs
Cost-Benefit Analysis
Ecosystem
Patient Care
Biomarkers
Delivery of Health Care
Pressure
Therapeutics
Clinical Decision-Making

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Abernethy, A., Abrahams, E., Barker, A., Buetow, K., Burkholder, R., Dalton, W. S., ... Van'T Veer, L. (2014). Turning the tide against cancer through sustained medical innovation: The pathway to progress. Clinical Cancer Research, 20(5), 1081-1086. https://doi.org/10.1158/1078-0432.CCR-13-3430

Turning the tide against cancer through sustained medical innovation : The pathway to progress. / Abernethy, Amy; Abrahams, Edward; Barker, Anna; Buetow, Kenneth; Burkholder, Randy; Dalton, William S.; Foti, Margaret; Frueh, Felix; Gaynor, Richard B.; Kean, Marcia; Khan, Zeba; Lessor, Tracy; Lichtenfeld, J. Leonard; Mendelsohn, John; Van'T Veer, Laura.

In: Clinical Cancer Research, Vol. 20, No. 5, 2014, p. 1081-1086.

Research output: Contribution to journalArticle

Abernethy, A, Abrahams, E, Barker, A, Buetow, K, Burkholder, R, Dalton, WS, Foti, M, Frueh, F, Gaynor, RB, Kean, M, Khan, Z, Lessor, T, Lichtenfeld, JL, Mendelsohn, J & Van'T Veer, L 2014, 'Turning the tide against cancer through sustained medical innovation: The pathway to progress', Clinical Cancer Research, vol. 20, no. 5, pp. 1081-1086. https://doi.org/10.1158/1078-0432.CCR-13-3430
Abernethy, Amy ; Abrahams, Edward ; Barker, Anna ; Buetow, Kenneth ; Burkholder, Randy ; Dalton, William S. ; Foti, Margaret ; Frueh, Felix ; Gaynor, Richard B. ; Kean, Marcia ; Khan, Zeba ; Lessor, Tracy ; Lichtenfeld, J. Leonard ; Mendelsohn, John ; Van'T Veer, Laura. / Turning the tide against cancer through sustained medical innovation : The pathway to progress. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 5. pp. 1081-1086.
@article{5c7d021ae6a44a908becce5319fd793f,
title = "Turning the tide against cancer through sustained medical innovation: The pathway to progress",
abstract = "An ever-expanding understanding of the molecular basis of the more than 200 unique diseases collectively called cancer, combined with efforts to apply these insights to clinical care, is forming the foundation of an era of personalized medicine that promises to improve cancer treatment. At the same time, these extraordinary opportunities are occurring in an environment of intense pressure to contain rising healthcare costs. This environment presents a challenge to oncology research and clinical care, because both are becoming progressively more complex and expensive, and because the current tools to measure the cost and value of advances in care (e.g., comparative effectiveness research, cost-effectiveness analysis, and health technology assessments) are not optimized for an ecosystem moving toward personalized, patient-centered care. Reconciling this tension will be essential to maintaining progress in a cost-constrained environment, especially because emerging innovations in science (e.g., increasing identification of molecular biomarkers) and in clinical process (implementation of a learning healthcare system) hold potential to dramatically improve patient care, and may ultimately help address the burden of rising costs. For example, the rapid pace of innovation taking place within oncology calls for increased capability to integrate clinical research and care to enable continuous learning, so that lessons learned from each patient treated can inform clinical decision making for the next patient. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration. This article reflects and seeks to amplify the ongoing robust discussion and diverse perspectives brought to this issue by multiple stakeholders within the cancer community, and to consider how to frame the research and regulatory policies necessary to sustain progress against cancer in an environment of constrained resources.",
author = "Amy Abernethy and Edward Abrahams and Anna Barker and Kenneth Buetow and Randy Burkholder and Dalton, {William S.} and Margaret Foti and Felix Frueh and Gaynor, {Richard B.} and Marcia Kean and Zeba Khan and Tracy Lessor and Lichtenfeld, {J. Leonard} and John Mendelsohn and {Van'T Veer}, Laura",
year = "2014",
doi = "10.1158/1078-0432.CCR-13-3430",
language = "English (US)",
volume = "20",
pages = "1081--1086",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Turning the tide against cancer through sustained medical innovation

T2 - The pathway to progress

AU - Abernethy, Amy

AU - Abrahams, Edward

AU - Barker, Anna

AU - Buetow, Kenneth

AU - Burkholder, Randy

AU - Dalton, William S.

AU - Foti, Margaret

AU - Frueh, Felix

AU - Gaynor, Richard B.

AU - Kean, Marcia

AU - Khan, Zeba

AU - Lessor, Tracy

AU - Lichtenfeld, J. Leonard

AU - Mendelsohn, John

AU - Van'T Veer, Laura

PY - 2014

Y1 - 2014

N2 - An ever-expanding understanding of the molecular basis of the more than 200 unique diseases collectively called cancer, combined with efforts to apply these insights to clinical care, is forming the foundation of an era of personalized medicine that promises to improve cancer treatment. At the same time, these extraordinary opportunities are occurring in an environment of intense pressure to contain rising healthcare costs. This environment presents a challenge to oncology research and clinical care, because both are becoming progressively more complex and expensive, and because the current tools to measure the cost and value of advances in care (e.g., comparative effectiveness research, cost-effectiveness analysis, and health technology assessments) are not optimized for an ecosystem moving toward personalized, patient-centered care. Reconciling this tension will be essential to maintaining progress in a cost-constrained environment, especially because emerging innovations in science (e.g., increasing identification of molecular biomarkers) and in clinical process (implementation of a learning healthcare system) hold potential to dramatically improve patient care, and may ultimately help address the burden of rising costs. For example, the rapid pace of innovation taking place within oncology calls for increased capability to integrate clinical research and care to enable continuous learning, so that lessons learned from each patient treated can inform clinical decision making for the next patient. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration. This article reflects and seeks to amplify the ongoing robust discussion and diverse perspectives brought to this issue by multiple stakeholders within the cancer community, and to consider how to frame the research and regulatory policies necessary to sustain progress against cancer in an environment of constrained resources.

AB - An ever-expanding understanding of the molecular basis of the more than 200 unique diseases collectively called cancer, combined with efforts to apply these insights to clinical care, is forming the foundation of an era of personalized medicine that promises to improve cancer treatment. At the same time, these extraordinary opportunities are occurring in an environment of intense pressure to contain rising healthcare costs. This environment presents a challenge to oncology research and clinical care, because both are becoming progressively more complex and expensive, and because the current tools to measure the cost and value of advances in care (e.g., comparative effectiveness research, cost-effectiveness analysis, and health technology assessments) are not optimized for an ecosystem moving toward personalized, patient-centered care. Reconciling this tension will be essential to maintaining progress in a cost-constrained environment, especially because emerging innovations in science (e.g., increasing identification of molecular biomarkers) and in clinical process (implementation of a learning healthcare system) hold potential to dramatically improve patient care, and may ultimately help address the burden of rising costs. For example, the rapid pace of innovation taking place within oncology calls for increased capability to integrate clinical research and care to enable continuous learning, so that lessons learned from each patient treated can inform clinical decision making for the next patient. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration. This article reflects and seeks to amplify the ongoing robust discussion and diverse perspectives brought to this issue by multiple stakeholders within the cancer community, and to consider how to frame the research and regulatory policies necessary to sustain progress against cancer in an environment of constrained resources.

UR - http://www.scopus.com/inward/record.url?scp=84895791424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895791424&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-3430

DO - 10.1158/1078-0432.CCR-13-3430

M3 - Article

C2 - 24523437

AN - SCOPUS:84895791424

VL - 20

SP - 1081

EP - 1086

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -